Expansion of Everest Medicine’s licence agreement to include South Korea
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has expanded its licensing agreement with Everest Medicines II Limited (HKG: 1952) (“Everest”) to extend the territory covered to include South Korea.“We continue to have a fruitful and positive collaboration with Everest and are delighted that we have come to an agreement also around South Korea,” said CEO Renée Aguiar-Lucander. The extension results in an upfront payment of USD 3 million to Calliditas as well as additional payments and royalties related to future potential